Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) FCF Margin (2020 - 2026)

Rani Therapeutics Holdings' FCF Margin history spans 5 years, with the latest figure at 381.44% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 438600.0% to 381.44% in Q1 2026 year-over-year; TTM through Mar 2026 was 540.14%, a 233853.0% increase, with the full-year FY2025 number at 1151.38%, up 232761.0% from a year prior.
  • FCF Margin came in at 381.44% for Q1 2026, down from 19.58% in the prior quarter.
  • The five-year high for FCF Margin was 19.58% in Q4 2025, with the low at 4767.44% in Q1 2025.
  • Historically, FCF Margin has averaged 1493.56% across 3 years, with a median of 613.19% in 2024.
  • Biggest five-year swings in FCF Margin: soared 86452bps in 2025 and later surged 438600bps in 2026.
  • Year by year, FCF Margin stood at 844.94% in 2024, then surged by 102bps to 19.58% in 2025, then tumbled by -2049bps to 381.44% in 2026.
  • Business Quant data shows FCF Margin for RANI at 381.44% in Q1 2026, 19.58% in Q4 2025, and 4767.44% in Q1 2025.